SAFC Pharma expands Pharmorphix solid state chemistry services
SAFC, a member of the Sigma-Aldrich Group, has announced the second-phase of a US$600,000 (Euro 404,000) expansion of its solid-state services Pharmorphix research facility in Cambridge, UK, which will add 7,500ft2 of laboratory capacity.
SAFC, a member of the Sigma-Aldrich Group, has announced the second-phase of a US$600,000 (Euro 404,000) expansion of its solid-state services Pharmorphix research facility in Cambridge, UK, which will add 7,500ft2 of laboratory capacity.
As part of a multi-phase development programme the additional, fully refitted space is scheduled for completion in the first quarter of 2008 and will augment the current 12,500ft2 facility. The development includes office reorganisation and will facilitate installation later this year of additional state-of-the-art spectroscopic and diffraction equipment.
"As new drugs and the regulatory climate continue to become more complex, testing analysis and optimisation of APIs play an increasingly key role in drug development. Through our Pharmorphix solid-state research services SAFC Pharma is a recognised and capable player in this complex field," said SAFC Pharma vice president of manufacturing and European operations, Michael Harris.
"The additional facilities reinforce our commitment to support customers in niche technologies and are expected to support SAFC business growth from Europe, the US and, increasingly, from Asia Pacific."
This new expansion follows a recently announced $12m (€8m) expansion of SAFC Pharma's viral product manufacturing facility in Carlsbad, California, and the Pharmorphix services launch in the US at its flagship high-potent manufacturing facility in Madison, Wisconsin, with new XRPD (X-ray Powder Diffraction) analytical equipment.
Other recently announced investments include a $10m (€6.7m) expansion of commercial-scale APIs manufacturing and storage capacity, respectively, at Arklow, Ireland and Buchs, Switzerland, a $29m (€19.5 m) potent-fermentation expansion in Jerusalem, Israel, and a high-potent API conjugation suite at the St Louis manufacturing campus, Missouri.